BRIEF published on 09/15/2026 at 15:40, 17 days 21 hours ago Revive Therapeutics vise à élargir son portefeuille de produits à base de bucillamine. Propriété Intellectuelle Maladies Orphelines Contre-mesures Médicales Bucillamine Partenariats Gouvernementaux
BRIEF published on 09/15/2026 at 15:40, 17 days 21 hours ago Revive Therapeutics Aims to Expand Bucillamine Portfolio Intellectual Property Orphan Diseases Medical Countermeasures Government Partnerships Bucillamine
PRESS RELEASE published on 09/15/2026 at 15:35, 17 days 21 hours ago Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases Revive Therapeutics Ltd. outlines strategy to build protected bucillamine franchise for medical countermeasures, rare diseases, and government preparedness programs Rare Diseases Medical Countermeasures Revive Therapeutics Ltd. Bucillamine Franchise Government Preparedness
BRIEF published on 08/19/2026 at 20:40, 1 month 14 days ago Revive Therapeutics Proposes Shares for Debt Settlement Debt Settlement Canadian Securities Exchange Shares Issuance Revive Therapeutics Biodefense Research
BRIEF published on 08/19/2026 at 20:40, 1 month 14 days ago Revive Therapeutics propose des actions en échange du règlement de sa dette Émission D'actions Règlement De Dettes Bourse Canadienne Des Valeurs Mobilières Revive Therapeutics Recherche En Biodéfense
PRESS RELEASE published on 08/19/2026 at 20:35, 1 month 14 days ago Revive Therapeutics Announces Proposed Shares for Debt Settlement Revive Therapeutics Ltd. announces proposed debt settlement by issuing Settlement Shares to settle outstanding trade payables. Subject to CSE approval Debt Settlement Settlement Shares CSE Approval Revive Therapeutics Ltd. Biodefence
BRIEF published on 08/19/2026 at 14:45, 1 month 14 days ago Revive Therapeutics fait progresser sa stratégie de biodéfense avec la bucillamine Biodefense Contre-mesures Médicales Préparation Aux Pandémies Bucillamine Partenariats Gouvernementaux
BRIEF published on 08/19/2026 at 14:45, 1 month 14 days ago Revive Therapeutics Advances Biodefence Strategy with Bucillamine Medical Countermeasures Pandemic Preparedness Government Partnerships Bucillamine Biodefence
PRESS RELEASE published on 08/19/2026 at 14:40, 1 month 14 days ago Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio Revive plans to expand bucillamine use in biodefence with positive DRDC findings, government opportunities, and complementary therapies, focusing on medical countermeasures Bucillamine Biodefence Revive DRDC Government Opportunities
BRIEF published on 08/15/2026 at 00:55, 1 month 19 days ago Revive Therapeutics Grants 15.5 Million Stock Options Stock Options Life Sciences Biodefense Pandemic Preparedness Revive Therapeutics
Published on 10/03/2026 at 02:35, 10 hours 59 minutes ago Jaguar Health Announces a Special Stock Dividend
Published on 10/02/2026 at 13:50, 23 hours 44 minutes ago AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 1 day ago Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 1 day ago Alaska Energy Metals Appoints Independent Director, Thomas Benson
Published on 10/02/2026 at 23:55, 13 hours 39 minutes ago IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 17 hours 10 minutes ago EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Published on 10/02/2026 at 19:46, 17 hours 47 minutes ago innoscripta SE: Update on the Tax Authorities’ Investigation – Business Operations Continue as Usual – Full Transparency Assured – Invitation to Shareholders for an In-Person Product Presentation
Published on 10/02/2026 at 19:00, 18 hours 34 minutes ago INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 10/02/2026 at 18:00, 19 hours 34 minutes ago EQS-Adhoc: AMUNDI PHYSICAL GOLD ETC (the “ETC”): Release of the first Supplemental Base Prospectus (the “Supplemental”)
Published on 10/02/2026 at 17:45, 19 hours 49 minutes ago Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:45, 19 hours 49 minutes ago Informations relatives au nombre total de droits de vote et d’actions 2026 09 30
Published on 10/02/2026 at 17:35, 19 hours 59 minutes ago Peugeot Invest - Déclaration du nombre d'actions et de droits de vote
Published on 10/02/2026 at 17:30, 20 hours 4 minutes ago Aéroports de Paris SA - 2027 Financial Calendar
Published on 10/02/2026 at 17:30, 20 hours 4 minutes ago Aéroports de Paris SA - Calendrier financier 2027
